

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
1073 daily bars · split adjusted
Current price $10.27
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jan 23, 26 | Barclays | upgrade |
Daily · Wilder smoothing
| Equal Weight |
| Overweight |
| Sep 16, 25 | Barclays | downgrade | Overweight | Equal Weight |
| Sep 20, 24 | Morgan Stanley | maintain | Overweight | Overweight |
| Mar 26, 24 | Argus Research | maintain | Buy | Buy |
| Apr 6, 23 | Argus Research | upgrade | Hold | Buy |
| Sep 28, 22 | Argus Research | maintain | Hold | Hold |
| Jul 29, 22 | Deutsche Bank | maintain | Hold | Hold |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 67.92 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 91.76 | Oscillator | Sell |
| Williams %R (14) | -7.91 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.24 (Hist 0.12) | Oscillator | Strong Buy |
| Average Directional Index (14) | 31.20 (+DI 41.6 / -DI 14.4) | Trend | Strong Buy |
| EMA 20 | 9.72 | MA | Strong Buy |
| SMA 20 | 9.49 | MA | Strong Buy |
| EMA 50 | 9.59 | MA | Strong Buy |
| SMA 50 | 9.56 | MA | Strong Buy |
| SMA 200 | 9.78 | MA | Strong Buy |
Stock news · updated daily
UBS, the Swiss investment bank, says an early rise in flu incidence could lift 2027 earnings forecasts for Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY), the consumer goods group, and Haleon, the consumer health group. The bank rates Reckitt 'buy' with a price target of 7,600p, implying 39% upside from its Monday closing price of 5,484p.
Limited-time experience invites Canadians to explore trusted health solutions, connect with experts and discover practical ways to support their wellbeing Limited-time experience invites Canadians to explore trusted health solutions, connect with experts and discover practical ways to support their wellbeing
Nostalgia-fueled experience introduces Excedrin Rapid Relief, providing fast relief of tough pain that starts in as little as 15 minutes Key Takeaways: Excedrin is introducing My Little Headache, a nostalgic digital-pet experience inspired by the handheld toys of the late '90s and early 2000s, capitalizing on the renewed popularity of digital pets among nostalgia-seeking consumers The interactive experience turns headache disruption into a playful, hard-to-ignore virtual pet that escalates through alerts, animations, and reactions As the digital pet becomes increasingly demanding, My Little Headache reminds consumers that headaches do not wait, and neither should relief. With Excedrin Rapid Relief's patented Fast Release Technology starting to provide relief in as little as 15 minutes, the pet transforms alongside the experience, playfully bringing to life the feeling of leaving headache pain behind and getting back to yourself Singer and actor Jesse McCartney helps bridge nostalgia and contemporary culture, reconnecting with longtime fans while building relevance with a new generation WARREN, N.J.
Goldman Sachs handpicks European stocks with the highest conviction for outperformance, and four of October's top selections carry a benefit most growth-focused investors overlook entirely.
Unilever PLC (LSE:ULVR) is on JP Morgan's 'positive watch', and Haleon PLC (LSE:HLN, NYSE:HLN) on 'negative watch', ahead of third-quarter reporting by European consumer staples companies. The note adds Givaudan to positive watch alongside Unilever, Heineken N.V.
Investors interested in stocks from the Consumer Products - Discretionary sector have probably already heard of Lifetime Brands (LCUT) and Haleon PLC Sponsored ADR (HLN). But which of these two companies is the best option for those looking for undervalued stocks?
Consumer health company Haleon has achieved growing sales of products to counter side-effects of weight-loss drugs in the United States, the company said, capitalising on the rising popularity of GLP-1 medication.
Investors with an interest in Consumer Products - Discretionary stocks have likely encountered both Lifetime Brands (LCUT) and Haleon PLC Sponsored ADR (HLN). But which of these two stocks offers value investors a better bang for their buck right now?
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | 0.27 | 0.28 | Beat 3.6% | $7.52B |
| Feb 25, 2026 | 0.25 | 0.26 | Beat 3.4% | $7.51B |
| Jul 31, 2025 | 0.24 | 0.24 | Miss -0.6% | $7.25B |
| Feb 27, 2025 | 0.22 | 0.23 | Beat 5.2% | $7.14B |
| Oct 31, 2024 | 0.11 | 0.23 | Beat 109.4% | $7.28B |
| May 1, 2024 | 0.11 | 0.12 | Beat 9.1% | $7.04B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 6-K | Oct 1, 2026 | 2026-10-01 06:16:10 | View |
| 6-K | Sep 24, 2026 | 2026-09-24 07:44:02 | View |
| 6-K | Sep 18, 2026 | 2026-09-18 07:46:59 | View |
| 6-K | Sep 1, 2026 | 2026-09-01 07:51:06 | View |
| CERT | Aug 26, 2026 | 2026-08-26 11:24:53 | View |
| 8-A12B | Aug 21, 2026 | 2026-08-21 15:28:36 | View |
| 6-K | Aug 21, 2026 | 2026-08-21 13:18:39 | View |
| 6-K | Aug 19, 2026 | 2026-08-19 08:22:49 | View |
| 6-K | Aug 19, 2026 | 2026-08-19 06:12:57 | View |
| 6-K | Aug 17, 2026 | 2026-08-17 06:48:00 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | HLN | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 21.0x | 23.5x · sector 20.7x | In line |
| Forward P/E (FY26E) | 24.4x | EPS est. 0.42 | Elevated |
| Price / Book | 2.1x | 1.8x | Elevated |
| Price / Sales | 3.0x | 2.9x | In line |
| EV / EBITDA | 14.0x | 15.4x | In line |
| Return on equity | 9.9% | — | Weak |
| Gross margin | 65.6% | 61.9% | In line |
| Debt / Equity | 0.50 | 0.48 | Moderate |
| Piotroski / Altman Z | 8/9 | Z 2.99 | Grey zone |
Discounted cash flow model
FY2025 · 10-K disclosure
FY2022 · 10-K disclosure